AUSTIN, Texas, May 22, 2018 /PRNewswire/ -- Altogen Biosystems announced the launch of AltoFect, the second generation transfectionreagent for primary cell types and hard-to-transfect cell lines. AltoFect transfection reagent exhibits up to 85% transfection efficiency in difficult-to-transfect cells such as T-cells, B-cells, and primary cell cultures. The advance has opened up the
Primary cells, derived directly from tissues, have historically exhibited low transfection efficiency due to the natural characteristics present in the tissue of origin. However, these cells are more relevant as disease model for research applications, preclinical testing, and drug development. The response of the cultured primary cells to transfection will mimic that of cells in tissues and will allow to predict cytotoxicity and off-target effects.
Transfection methods are commonly used in research laboratories for gene function and gene expression studies, library screening, mutational analysis, RNAi studies, preclinical testing, and recombinant protein bio-production. AltoFect transfection reagent enables researchers to overcome the challenges and limitations related to primary cells and difficult-to-transfect cell lines. This reagent can be utilized for transient and stable transfection and to establish inducible cell lines, which is essential for cells resistant to transfection with standard reagents. AltoFect is a reliable experimental tool suitable for transfection of sensitive cell types (such as primary neuronal cell cultures) as it exhibits low cytotoxicity yielding the high transfection efficiency. Transfection reagent is compatible for intracellular delivery of various negatively charged cargo molecules, including plasmid DNA, RNA (mRNA and siRNA), and small proteins.
About Altogen Biosystems
Altogen Biosystems (www.altogen.com) is leading manufacturer of cell line optimized transfection products for in vitro and in vivo life sciences research applications. Altogen Biosystems provides over 120 transfection products for biomedical research, including cell type-specific transfection reagents, electroporation kits, and in vivo tissue-targeted delivery reagents.
Altogen Labs (www.altogenlabs.com) provides laboratory contract research services including all types of preclinical testing. Biology CRO services include compound testing in over 100 xenograft models (89 CDX and 29 PDX xenograft models), pharm/tox assays, generation of stable cell lines, genome-wide library screening, liposome encapsulation, assay development (ELISA, IC-50, Caspase-3/7), RNAi, and in vivo toxicology.
848 Rainbow Blvd #823
Las Vegas NV 89107
View original content:http://www.prnewswire.com/news-releases/altogen-biosystems-launched-second-generation-transfection-reagent-altofect-300652952.html
SOURCE Altogen Biosystems
Subscribe to our Free Newsletters!